US2016095922A1PendingUtilityA1
Selective resonance of bodily agents
Est. expiryJul 21, 2025(expired)· nominal 20-yr term from priority
A61M 37/0092A61N 5/00A61K 41/0004G16B 5/00G16B 15/00A61B 2018/00577G16B 40/00A61N 5/062A61B 5/0059
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 .- 22 . (canceled)
23 . A method, comprising
identifying a naturally-occurring agent in a body; selecting a set of differing energy inputs specific to the agent, wherein the set of differing energy inputs selectively resonates a plurality of resonant structures in the agent; and directing the set of differing energy inputs towards the agent.
24 . The method of claim 23 , wherein the agent has a metabolic effect in the body.
25 . The method of claim 24 , wherein directing the set of differing energy inputs towards the agent modulates the metabolic effect in the body.
26 .- 28 . (canceled)
29 . The method of claim 24 , wherein directing the set of differing energy inputs towards the agent destroys the agent.
30 .- 34 . (canceled)
35 . The method of claim 23 , wherein the body is alive.
36 . The method of claim 23 , wherein the body is human.
37 . The method of claim 23 , wherein the agent is present in blood.
38 . The method of claim 37 , wherein directing the set of differing energy inputs towards the agent comprises directing the set of differing energy inputs into the body.
39 . The method of claim 37 , wherein directing the set of differing energy inputs towards the agent comprises treating the blood by directing the set of differing energy inputs into the blood external from the body, and the method further comprises introducing the treated blood into the body.
40 . The method of claim 23 , further comprising monitoring the body for activity of the agent.
41 . The method of claim 23 , further comprising monitoring the body for quantity of the agent.
42 . (canceled)
43 . The method of claim 23 , further comprising modifying the agent in the body to add a functional group selected to be responsive to the set of differing energy inputs.
44 . The method of claim 23 , wherein the agent is selected from the group consisting of blood clotting factors, sugars, lipids, lipoproteins, vitamins, minerals, hormones, enzymes, antibodies, and proteins.
45 . The method of claim 44 , wherein the agent is a blood clotting factor selected from the group consisting of prekallikrein, high molecular weight kininogen, clotting factors I-XIII, von Willebrand factor, protein C, protein S, thrombomodulin, and antithrombin III.
46 . The method of claim 44 , wherein the agent is a sugar selected from the group consisting of glucose, fructose, sucrose, galactose, mannose, glycerol, and glucuronate.
47 . The method of claim 44 , wherein the agent is a lipid or lipoprotein selected from the group consisting of cholesterol, triglicerides, triacylglycerols, chylomicrons, very low density lipoproteins, low density lipoproteins, intermediate density lipoproteins, and high density lipoproteins.
48 . The method of claim 44 , wherein the agent is a hormone selected from the group consisting of adrenalin, adrenocorticotropic hormone, aldosteron, calcitonin, cortisol, insulin, gastrin, glucagon, glucocorticoids, thyroid hormone, gastrin, secretin, cholecystokinin, somatostatin, neuropeptide Y, other hormones of the gut, thyrotropin-releasing hormone, gonadotropin-releasing hormone, growth hormone-releasing hormone, ghrelin, corticotrophin-releasing hormone, somatostatin, dopamine, antidiuretic hormone, oxytocin, other hormones of the hypothalamus, renin, erythropoietin, calcitrol, other hormones of the kidney, insulin-like growth factor-1, angiotensinogen, thrombopoietin, other hormones of the liver, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, prolactin, growth hormone, adrenocorticotropic hormone, antidiuretic hormone, other hormones of the pituitary, estrogen, testosterone, progesterone, anabolic steroids, other reproductive hormones, melanocyte-stimulating hormone, parathyroid hormone, melatonin, prolactin, and thyroid hormones.
49 . The method of claim 44 , wherein the agent is an enzyme selected from the group consisting of creatine kinase, lactate dehydrogenase, troponin, other cardiac enzymes, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyltranspeptidase, and other liver enzymes.
50 . The method of claim 44 , wherein the agent is an antibody to an autoimmune disorders selected from the group consisting of acute transverse myelitis, allergic (Henoch-Schönlein) purpura, alopecia areata, aplastic anemia, brachial neuritis, bullous pemphigoid, dermatitis herpetiformis, polymyositis, dermatomyositis, Eaton-Lambert syndrome, eosinophilic fasciitis, Goodpasture's syndrome, Guillain-Barré syndrome, hemolytic anemia, hepatitis, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus, peripheral ulcerative keratitis, polyglandular deficiency syndrome, relapsing polychondritis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and system lupus erythematosus,
51 . The method of claim 44 , wherein the agent is an antibody to a transplanted material.
52 . The method of claim 51 , wherein the transplanted material is selected from the group consisting of organs, stem cells, and device implants.
53 . The method of claim 44 , wherein the agent is a protein selected from the group consisting of albumins, globulins, fibrinogens, and hemoglobins.Join the waitlist — get patent alerts
Track US2016095922A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.